Such insights could guide targeted therapeutic strategies designed to modulate these mutational patterns, reprogram NAT10 distribution, and thereby inhibit cancer progression.Similarly, in colorectal cancer, aberrant subcellular localization of NAT10 is observed, driven primarily by inhibition of glycogen synthase kinase 3β (GSK-3β). This evidence concerns the gene NAT10 and cancer.